RMJH-111b is under clinical development by RMJ Holdings and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect RMJH-111b’s likelihood of approval (LoA) and phase transition for Idiopathic (Essential) Hypertension took place on 26 Sep 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RMJH-111b Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

RMJH-111b overview

RMJH-111b is under development for the treatment of essential hypertension. It is administered as soft gelatin capsules through oral route. The drug candidate is developed based on inverted micellar technology.

Quick View RMJH-111b LOA Data

Report Segments
  • Innovator
Drug Name
  • RMJH-111b
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.